Gabriele et al. reply

doi:10.1038/s41587-025-02943-y

2025-12-02

PRE

DOI：10.1038/s41587-025-02943-y

原文链接

原文求助

摘要

期刊

Nature Biotechnology

IF:

41.7

论文数:

1.2W

被引数:

10.1W

机构

暂无机构信息

引用论文

Rethinking Innovation in Drugs: A Pathway to Health for All 重新思考药物创新：一条通往全民健康的道路

Journal of Law, Medicine & Ethics

IF0

2024-03-04

OAAI

Mariana Mazzucato

What if NIH had been 40% smaller?如果NIH的规模缩小了40%会怎样？

Science

IF45.8

2025-09-25

PREAI

Pierre Azoulay; Matthew Clancy; Danielle Li; Bhaven N. Sampat

The strength and importance of government-funded patents for approved drugs 政府资助专利在获批药物中的强度与重要性

Nature Biotechnology

IF41.7

2025-07-15

PREAI

Sarah M. E. Gabriele; Matthew J. Martin; Aaron S. Kesselheim; S. Sean Tu

Revisiting the National Institutes of Health Fair Pricing Condition: Promoting the Affordability of Drugs Developed With Government Support

ANNALS OF INTERNAL MEDICINE

IF15.2

2020-03-03

PREAI

Sarpatwari, Ameet; LaPidus, Alison K.; Kesselheim, Aaron S.

Spending on Phased Clinical Development of Approved Drugs by the US National Institutes of Health Compared With Industry

JAMA HEALTH FORUM

IF11.3

2023-07-14

OAAI

Zhou, Edward W.; Jackson, Matthew J.; Ledley, Fred D.